![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/8/89/Antibody-drug_conjugate_structure.svg/640px-Antibody-drug_conjugate_structure.svg.png&w=640&q=50)
Antibody–drug conjugate
Class of biopharmaceutical drugs / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Antibody–drug conjugate?
Summarize this article for a 10 year old
Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer.[1] Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.[2]
![Thumb image](http://upload.wikimedia.org/wikipedia/commons/thumb/8/89/Antibody-drug_conjugate_structure.svg/320px-Antibody-drug_conjugate_structure.svg.png)
ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug.[3] Antibody–drug conjugates are an example of bioconjugates and immunoconjugates.
ADCs combine the targeting properties of monoclonal antibodies with the cancer-killing capabilities of cytotoxic drugs, designed to discriminate between healthy and diseased tissue.[4][5]